The [almost] unbelievable relationship between “big pharma” and gray-market peptides
Preview text: We traced the patent and development histories of 25 popular compounds, uncovering ties to…
![The [almost] unbelievable relationship between “big pharma” and gray-market peptides - email from Peter Attia, M.D.](https://img.theysentit.com/peter-attia-md/5204895.jpg)
Use this example
- Subject
- The [almost] unbelievable relationship between “big pharma” and gray-market peptides
- Preview text
- We traced the patent and development histories of 25 popular compounds, uncovering ties to…
- From
- peter@
peterattiamd.com - Brand
- Peter Attia, M.D.
- ESP
- Klaviyo
- Sent
- Sun Oct 18, 2026, 7:00 AM ET
- Sent to
- attiamedical.com, peterattiamd.com
- Size
- 50 KB
- Images
- 6
- Links
- 9, 5 of them buttons
- Subject length
- 84 characters
Against Peter Attia, M.D.'s usual
Sent in its busiest hour, 7 AM, which holds 100% of its emails. The subject is 84 characters; its average is 66.
Email headers
What the brand's servers put on this email. Our receiving servers, the address we subscribed with and unsubscribe links are left out.
- From
- Peter Attia, M.D. <[email protected]>
- Subject
- The [almost] unbelievable relationship between “big pharma” and gray-market peptides
- Date
- Sun, 18 Oct 2026 11:00:09 +0000
- Message-ID domain
- klaviyomail.com
- Return-Path domain
- k3.send.peterattiamd.com
- DKIM signature
- d=shared.klaviyomail.com s=def1; d=send.peterattiamd.com s=mtd1
- List-Unsubscribe
- Present, one-click
Servers it passed through, newest first
- from (unnamed) by kmta-mta-blue-….servers.clovesoftware.com with SMTP
Other sending headers (names only): X-Mailer-Info-Extra2, X-Mailer-Info, X-Mailer-Info-Extra, X-Kmail-Account, X-Kmail-Message, X-Kmail-Ops, X-Report-Abuse
Sent just before and after
| Oct 26, 2026 7:01 AM | The neuroscience of emotion: challenging conventional theories of emotion, how the brain predicts and constructs our experiences, and gaining greater control over how we feel | |
| Oct 25, 2026 7:03 AM | Personalized medicine comes to cancer immunotherapy | |
| Oct 19, 2026 7:01 AM | The evolving science of cancer: emerging approaches to prevention and early detection, and the advances reshaping treatment | |
| Oct 18, 2026 7:00 AM | The [almost] unbelievable relationship between “big pharma” and gray-market peptides (this email) | |
| Oct 12, 2026 7:02 AM | Strong convictions, loosely held: how Peter’s views on fasting, keto, metformin, rapamycin, whole-body MRI, and exercise have changed | |
| Oct 11, 2026 7:02 AM | How much do symptomatic treatments for Alzheimer’s disease help? | |
| Oct 5, 2026 7:02 AM | The biology of pregnancy: physiologic adaptation, gestational diabetes, preeclampsia, childbirth, and long-term maternal health |
More from Peter Attia, M.D.
All Peter Attia, M.D. emailsNov 9, 2026 7:02 AM
Nov 8, 2026 7:01 AM
Nov 2, 2026 7:02 AM
Who is actually at risk for CTE?
Nov 1, 2026 7:00 AM
A longevity playbook for building strength and muscle mass
Oct 29, 2026 7:00 AM
Oct 26, 2026 7:01 AM
Personalized medicine comes to cancer immunotherapy
Oct 25, 2026 7:03 AM
Oct 19, 2026 7:01 AM
Sent the same day by similar brands
Same ESP and the closest weekly volume, sent on Oct 18, 2026.









